Paricalcitol attenuates cyclosporine-induced kidney injury in rats  by Park, Jeong Woo et al.
see commentary on page 1055
Paricalcitol attenuates cyclosporine-induced
kidney injury in rats
Jeong Woo Park1, Eun Hui Bae1, In Jin Kim2, Seong Kwon Ma1, Chan Choi3, JongUn Lee2 and
Soo Wan Kim1
1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea; 2Department of Physiology,
Chonnam National University Medical School, Gwangju, Korea and 3Department of Pathology, Chonnam National University Medical
School, Gwangju, Korea
Despite its benefits, the clinical use of cyclosporine A (CsA)
is limited by its nephrotoxic properties. Because paricalcitol
(19-nor-1,25-hydroxyvitamin D2) has renoprotective effects,
we tested whether it can blunt renal dysfunction and fibrosis
in a rat model of CsA-induced nephropathy. Treatment with
CsA decreased creatinine clearance, increased monocyte/
macrophage infiltration, and increased the expression of
inflammatory cytokines within the kidney. Paricalcitol
reduced the decline in kidney function and pro-fibrotic
changes and also blunted the increased transforming growth
factor (TGF)-b1 expression and Smad signaling. Using an
in vitro model, we treated HK-2 cells with CsA and found
that paricalcitol attenuated the CsA-induced increases in
phosphorylated extracellular signal-regulated and c-Jun
N-terminal kinases, and also prevented the activation of
nuclear factor-jB. Paricalcitol effectively prevented
TGF-b1-induced epithelial-to-mesenchymal transitions and
extracellular matrix accumulation as evidenced by attenuated
collagen deposition and fibrosis in CsA-treated rats.
In addition, paricalcitol decreased the number of
TUNEL-positive nuclei and reduced the expression of
pro-apoptotic markers in CsA-treated HK-2 cells. Thus,
paricalcitol appears to attenuate CsA-induced nephropathy
by suppression of inflammatory, pro-fibrotic, and apoptotic
factors through inhibition of the nuclear factor-jB, Smad, and
mitogen-activated protein kinase signaling pathways.
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Deficiency in vitamin D and its active metabolites is a
common pathological feature in chronic kidney disease. In
addition to its primary role in calcium homeostasis and bone
mineralization, vitamin D is known to have an important
function in cellular homeostasis, including hormone secre-
tion, cell proliferation, and differentiation. Many previous
studies have focused on the effects of calcitriol, an active form
of vitamin D, or its analogs on glomerular damage,1–3
whereas kidney tubules, including the proximal tubule, have
been identified as another target of active vitamin D.4,5
The suppressive effect of calcitriol on renal interstitial
myofibroblasts indicates that calcitriol inhibits the develop-
ment of renal interstitial fibrosis.6 Paricalcitol (19-nor-1,
25-dihydroxyvitamin D2) is an active, nonhypercalcemic
vitamin D analog that shows similar biological activity, but
has fewer adverse effects and increased tolerance.7 Recently,
several investigators postulated that paricalcitol is renopro-
tective in various experimental nephropathy models through
its anti-inflammatory and anti-fibrotic actions.8–10
Cyclosporine A (CsA) is used to prevent rejection in
various types of organ transplantation and in the treatment
of many autoimmune diseases. Despite its clinical benefits,
the clinical use of CsA is limited by its nephrotoxic potential.
However, the mechanism for CsA-induced nephropathy
(CIN) is still incompletely understood and the molecular
basis remains undefined. CIN causes an irreversible decline
in renal function, which is characterized by both renal
vasoconstriction and structural damage, including arteriolar
hyalinosis, tubular atrophy, interstitial fibrosis, and glomer-
ular sclerosis.11,12 It has been known that CsA leads to
activation of the intrarenal renin–angiotensin system, which
reduces renal blood flow through the action of angiotensin II.
Angiotensin II has pleiotropic effects, including aldosterone
release, stimulation of tubular transport, pro-inflammatory
effects, and fibrogenic stimulatory actions, which are
mediated by transforming growth factor (TGF)-b signaling.
Local renal hypoxia or ischemia resulting from renal
vasoconstriction led to the production of reactive oxygen
species that caused cellular injury and promoted cell death by
apoptosis.13 CsA also directly activates apoptotic genes and
increases apoptosis in tubular and interstitial cells, resulting
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in tubular atrophy. In addition, inflammatory changes, such
as macrophage infiltration into the damaged kidney, are
associated with chronic CIN.14
TGF-b has a pivotal function in progressive renal disease,
including CIN. Importantly, CsA directly upregulates TGF-b
expression in tubular epithelial cells, independently of the
hemodynamic effects of the renin–angiotensin system in
chronic CIN.15,16 TGF-b promotes renal fibrosis by increas-
ing the production and decreasing the degradation of
extracellular matrix (ECM) components in the damaged
kidney. In addition, the inhibition of TGF-b using anti-TGF-b
antibodies reduced tubular epithelial apoptosis and decreased
the extent of tubular atrophy in an experimental model.17
These observations suggest that, beyond its effects on ECM
accumulation, TGF-b signaling may initiate renal tubular cell
pro-apoptotic effectors and the epithelial-to-mesenchymal
transition (EMT) in tubular epithelial cells, resulting in
tubular degeneration and tubular atrophy.
This study investigated the effect of paricalcitol on the
progression of CIN. To elucidate its mechanism of action, we
examined the effect of paricalcitol on renal inflammation,
apoptosis, fibrosis, and tubular epithelial integrity after
CsA-induced injury.
RESULTS
Functional parameters
Table 1 shows changes in functional parameters as a result of
CsA treatment. In rats, CsA increased plasma creatinine levels
and decreased creatinine clearance rate compared to controls.
Urine osmolality also decreased in the CsA-treated group
compared to controls. Urine albumin excretion increased
with CsA compared to controls. In contrast, paricalcitol
co-treatment attenuated the negative effects of CsA. The
mean blood CsA level was not significantly altered with
paricalcitol co-treatment.
Effects of paricalcitol on morphological changes in CIN
Figure 1 shows morphological change among three groups.
Hematoxylin and eosin staining revealed variable sizes of
tubular vacuolization, tubular atrophy associated with
cystic dilation in the proximal tubules in CsA-treated
rats compared with those in controls. Sparse interstitial
infiltration of mononuclear cells and widening of interstitial
spaces are also shown in CsA-treated rats. Paricalcitol
ameliorated these changes. Vimentin and Masson’s trichrome
staining confirmed that CsA induced collagen deposition and
fibrosis in the kidney, which were ameliorated by paricalcitol
(Figure 1a). Tubulointerstitial damage score and staining for
Masson’s trichrome significantly increased in CsA-treated
rats, which were attenuated by paricalcitol (Figure 1b).
Effects of paricalcitol on inflammatory cell infiltration,
inflammatory cytokines, and adhesion molecules in CIN
To determine the effects of paricalcitol on renal inflammatory
cell infiltration, we analyzed ED-1 protein expression and
the infiltration of ED-1-positive macrophages in renal tissue.
ED-1 expression in the cortex/outer stripe of the outer
medulla (OSOM) increased significantly in CsA-treated rats
compared to controls; paricalcitol attenuated increased ED-1
expression (Figure 2a). Similarly, paricalcitol co-treatment
abrogated the significant increase of ED-1-positive macro-
phages infiltration in CsA-treated animals (Figure 2b). The
expression of inducible nitric oxide synthase (iNOS), which is
synthesized during inflammation in renal disease, increased
in cortex/OSOM from CsA-treated rats compared to
controls, which was reversed by paricalcitol (Figure 2c).
We also investigated the expression of tumor necrosis
factor-a, interferon-g, and interleukin-1b, which are key
inflammatory cytokines produced by infiltrating cells. As
shown in Figure 3, CsA significantly induced renal tumor
necrosis factor-a, interleukin-1b, and interferon-g mRNA
expression; paricalcitol co-treatment attenuated these effects.
Certain chemokines and adhesion molecules, such as
monocyte chemoattractant protein-1, intercellular adhesion
molecule-1, and vascular cell adhesion molecule-1, which
activate or recruit the transmigration of inflammatory cells
into the site of renal injury, were also shown. CsA induced
the expression of these factors, which was also attenuated
by paricalcitol co-treatment.
Effects of paricalcitol on NF-jB expression in CIN
Nuclear factor-kB (NF-kB) is released from an inhibitory
subunit IkB and translocates into the nucleus, where it
promotes the transcriptional activation of target genes. We
assessed the effect of CsA (20 mmol/l) and paricalcitol on the
expression of phosphorylated NF-kB p65 subunit (P-p65) in
nuclear extracts and total IkB-a in cytoplasm of renal
proximal tubular epithelial cell line (HK-2). The nuclear
translocation of p65 subunits began to increase at 15min,
peaked at 30min after CsA exposure, and diminished
progressively afterward (Figure 4a). Cytoplasmic total
IkB-a expression was not changed in CsA-treated cells.
P-p65 expression was also examined in HK-2 cells, which
were pretreated with paricalcitol (0.2 ng/ml) for 3 h followed
by CsA (20 mmol/l) exposure for 30min. The expression
of P-p65 was increased in CsA-treated cells compared
to untreated controls, whereas paricalcitol pretreatment
Table 1 | Changes in renal functional parameters
Control CsA CsA+Pari
n 8 8 10
PCr (mg/dl) 0.4±0.0 0.9±0.1** 0.6±0.1
z
CCr (ml/min) 2.4±0.4 0.6±0.1* 1.2±0.2
w
UOsm (mOsm/kg H2O) 1294.0±49.2 534.4±18.1** 871.3±107.5
z
UAE (mg/g Cr) 4.3±0.5 12.7±1.1** 2.9±1.8z
CsA concentration
(ng/ml)
NM 2467.0±66.7 2376.0±31.4
Abbreviations: CCr, creatinine clearance; CsA, cyclosporine; n, number of rats; NM,
not measured; PCr, plasma creatinine; Pari, paricalcitol; UOsm, urine osmolality; UAE,
urine albumin excretion.
*Po0.05; **Po0.01 compared with control. wPo0.05; zPo0.01 compared with
CsA-treated rats.
Values are expressed as the mean±s.e.m.
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prevented this increase. Total IkB-a expression was equiva-
lent among three groups (Figure 4b).
Effects of paricalcitol on TGF-b1 and Smad signaling in CIN
Semiquantitative immunoblotting revealed that the expres-
sion of TGF-b1, an important pro-fibrotic molecule derived
from infiltrating inflammatory cells, increased significantly in
the cortex/OSOM of CsA-treated rats, and this effect was
markedly attenuated by paricalcitol. We also assessed the
TGF-b1-triggered Smad signaling pathway by evaluating the
total Smad-2/3 and Smad-4 levels and the level of inhibitory
Smad-6. An increase in total Smad-2/3 in CIN was
accompanied by an increase in Smad-4 content and a
decrease in inhibitory Smad-6 compared to the control
group. These CsA-induced changes were again restored by
paricalcitol co-treatment (Figure 5).
Effects of paricalcitol on ERK 1/2 and JNK expression in CIN
In HK-2 cells, CsA treatment (20 mmol/l) increased the levels
of phosphorylated extracellular signal-regulated kinase
(pERK) 1/2 compared to the control. In contrast, pretreat-
ment with paricalcitol (0.2 ng/ml) for 3 h before CsA
administration suppressed CsA-induced pERK overexpres-
sion. Phosphorylated c-Jun N-terminal kinase (pJNK)
expression also increased in HK-2 cells incubated with CsA,
and this effect was reversed by paricalcitol pretreatment
(Figure 6).
Effects of paricalcitol on EMT in CIN
We next examined the expression of the epithelial receptor
E-cadherin and a-smooth muscle actin (SMA), a molecular
marker of myofibroblasts. Figure 7 shows that paricalcitol
maintained E-cadherin expression and inhibited the
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Figure 1 |Representative microscopic findings (original magnification,  200). (a) Hematoxylin and eosin (H&E), vimentin, and
Masson’s trichrome (M-T) staining in rat kidneys. (b) Staining was quantified by image analysis. In H&E stain, tubular vacuolization and
atrophy were associated with dilation in the proximal tubules in CsA-treated rats compared with those in controls. Note the sparse
interstitial infiltration of mononuclear cells and widening of interstitial spaces also shown in CsA-treated rats. Paricalcitol ameliorated these
changes. Vimentin, a marker of actin microfilament and Masson’s trichrome staining, confirmed that CsA treatment increased collagen
deposition and fibrosis in the kidney, which were ameliorated by paricalcitol co-treatment. CsA, cyclosporine; Pari, paricalcitol. Each column
represents the mean±s.e.m. (n¼ 5). **Po0.01 compared to the control. zPo0.01 compared to CsA-treated rats.
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induction of a-SMA in CsA-treated rats, consistent with the
observed changes in TGF-b1 expression. In HK-2 cells, CsA
increased fibronectin and connective tissue growth factor
(CTGF) expression compared to the control, and this effect
was inhibited by paricalcitol pretreatment (Figure 8).
Effects of paricalcitol on renal tubular cell apoptosis in CIN
To determine the protective effects of paricalcitol on CsA-
induced renal tubular apoptosis, we performed terminal
deoxynucleotidyl transferase-mediated dUTP nick-end label-
ing (TUNEL). The number of tubular epithelial cells
containing TUNEL-positive nuclei increased in CsA-treated
rat kidney; paricalcitol co-treatment attenuated this effect
(Figure 9). Furthermore, CsA induced increases in pro-
apoptotic markers, such as Bax and total and cleaved caspase-
3 levels, which were attenuated by paricalcitol in HK-2 cells.
In contrast, the expression of anti-apoptotic protein Bcl-2
was decreased in renal tubular cells incubated with CsA,
which was also attenuated by paricalcitol (Figure 10).
Effects of paricalcitol on rat kidney and HK-2 cells
To ascertain the proper effects of paricalcitol on rat kidney
and HK-2 cells, we performed an experiment for another set
of rats and HK-2 cells, which were administrated vehicle or
buffer alone and paricalcitol alone. When comparing control
to paricalcitol group, there was no significant difference
in renal functional parameters (Supplementary Table S1).
The expression of inflammatory cytokines (Supplementary
Figure S1), P-p65, total IkB-a, and TGF-b1 was not altered
with paricalcitol. We also assessed the expression of mitogen-
activated protein kinases (MAPKs), EMT markers, apoptotic
markers, and anti-apoptotic markers in HK-2 cells, which
was not changed by paricalcitol (Supplementary Figure S2).
DISCUSSION
The infiltration of inflammatory cells into the interstitium is
a prominent pathological finding in progressive renal disease,
and these infiltrating inflammatory cells are important
sources of pro-fibrotic molecules, including TGF-b1.18,19
Chemokines and adhesion molecules are also activated, hence
recruit and induce the transmigration of inflammatory cells
into sites of renal injury. In this study, we showed that
paricalcitol reduced the CsA-induced increases in the levels of
chemokines, iNOS and adhesion molecules, and ED-1-
positive monocyte/macrophage infiltration, suggesting that
paricalcitol has an anti-inflammatory function.
Recent studies in CIN model, in which free radicals
induced oxidative stress, lead to the upregulation of iNOS
and NF-kB expression in response to CsA. In their studies,
chemical blockade using antioxidants reduced iNOS and
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Figure 2 | Effects of paricalcitol on inflammatory cell infiltration and inducible nitric oxide synthase (iNOS) expression.
(a) Semiquantitative immunoblotting of ED-1 expression. Inflammatory cell infiltration was determined by immunohistochemical staining
for ED-1, a specific marker of macrophages, in the cortex/outer stripe of the outer medulla (OSOM). (b) The infiltration of ED-1-expressing
cells increased significantly in CsA-treated rats, which was ameliorated by paricalcitol treatment (original magnification,  200). Arrows
indicate infiltrated ED-1-positive cells. (c) Semiquantitative immunoblotting of iNOS in cortex/OSOM. The expression of iNOS increased
during CsA challenge, compared to the control, and was counteracted by paricalcitol co-treatment. Each column represents the
mean±s.e.m. (n¼ 8). **Po0.01 compared to the control. zPo0.01 compared to CsA-treated rats. CsA, cyclosporine; Pari, paricalcitol.
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NF-kB overexpression.20,21 We also found that CsA increases
renal iNOS expression and nuclear translocation of p65
NF-kB subunit. Paricalcitol attenuated these changes,
suggesting that vitamin D exerts its immunomodulatory
effects in CIN through the regulation of NF-kB and NO
signaling. The mean blood CsA concentration was not
changed with paricalcitol co-treatment; hence, the beneficial
effect of paricalcitol on CIN was not attributed to the less
CsA exposition in rats.
TGF-b is a key molecule in renal disease progression.
Beyond its effect on ECM accumulation, TGF-b signaling
initiates renal tubular cell pro-apoptotic effectors and EMT in
tubular epithelial cells, resulting in tubular degeneration and
tubular atrophy. EMT is a process in which renal tubular cells
lose their epithelial phenotype and acquire new features of
the mesenchyme. We showed that TGF-b1 expression was
increased in CsA-treated rats, which was ameliorated by
paricalcitol co-treatment. TGF-b1 signals are transduced by
transmembrane serine/threonine kinase type I and type II
receptors and intracellular mediators known as Smads.
On TGF-b1 stimulation, receptor-bound Smad proteins,
such as Smad-2/3, are phosphorylated. Phosphorylation
induces the association of Smad-2/3 with Smad-4, a member
of the co-Smad subfamily, and they form transcriptionally
active complexes that translocate into the nucleus and
activate the transcription of TGF-b-induced target genes,
including CTGF. Smad signaling can also be negatively
controlled by the inhibitory Smad-6 and Smad-7 proteins.
For these reasons, TGF-b1-induced EMT is thought to be
mediated by Smad signaling.22,23 In this study, CsA induced
the overexpression of Smad-2/3 and Smad-4, whereas
inhibitory Smad-6 expression was decreased in response to
CsA. Importantly, paricalcitol effectively reversed these
effects. In addition, paricalcitol preserved E-cadherin expres-
sion and inhibited a-SMA induction in CsA-induced renal
injury. This suggests that paricalcitol may specifically target
tubular EMT, a key event in the pathogenesis of renal
interstitial fibrosis.
CsA also modulated the expression of MAPKs. Specifi-
cally, CsA-induced ERK 1/2 and c-JNK phosphorylation in
rat kidney, and these increases were attenuated by paricalci-
tol. In addition to Smad signaling, a comprehensive survey
indicated that TGF-b1 is capable of activating several other
signal transduction pathways in tubular epithelial cells, such
as MAPKs.24 TGF-b1 activates the ERK and JNK pathways,
and accumulating evidence suggests a function for these
signaling pathways in CIN. For example, ERK and PI3K
signaling may be involved in CsA-induced reactive oxygen
species generation and subsequent renal cell damage.25 Other
groups have also suggested that the activation of ERK
signaling has a critical function in the proliferation of tubular
epithelial and myofibroblast-like cells.26 JNK signaling is also
involved in TGF-b1-induced fibronectin and CTGF produc-
tion27 and interstitial myofibroblast accumulation28 suggest-
ing a function for JNK in renal fibrogenesis. In this study,
we showed that paricalcitol reduced ERK 1/2 and c-JNK
activation in CsA-treated rat kidneys. These changes coin-
cided with the expression of EMT markers, such as
E-cadherin and a-SMA, in vivo and the expression of CTGF
and fibronectin in HK-2 cells. Therefore, ERK 1/2 and c-JNK
signaling pathways activated by TGF-b1 appear to mediate
CsA-induced renal fibrosis, which is effectively inhibited by
paricalcitol. Masson’s trichrome staining confirmed the
paricalcitol-induced attenuation of collagen deposition and
fibrosis in CIN.
In progressive renal disease, tubular cell apoptosis
precedes manifestations of tubular atrophy, tubular dilata-
tion, and perivascular inflammation.23 Yang et al.29 also
showed that loss of cellularity progresses over time together
with the activation of apoptosis-related gene expression
until fibrotic tissue replaces the apoptotic cells in a chronic
CIN model. Accordingly, CsA induces Bax aggregation and
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Figure 3 | Effects of paricalcitol on inflammatory cytokines
and adhesion molecules. Real-time polymerase chain reaction
(PCR) was used to examine the expression of tumor necrosis
factor (TNF)-a, interferon (IFN)-g, and interleukin (IL)-1b, which are
pro-inflammatory cytokines that participate in the pathogenesis
of renal disease. Chemoattractants and adhesion molecules, such
as monocyte chemoattractant protein (MCP)-1, intercellular
adhesion molecule (ICAM)-1, and vascular cell adhesion molecule
(VCAM)-1, were also evaluated. These inflammatory cytokines are
significantly elevated in CsA-treated rats compared to those in
control rats. Paricalcitol co-treatment suppressed the CsA-induced
overexpression of these inflammatory cytokines and adhesion
molecules. Each column represents the mean±s.e.m. (n¼ 8).
*Po0.05 and **Po0.01 compared to the control. wPo0.05 and
zPo0.01 compared to CsA-treated rats. CsA, cyclosporine; Pari,
paricalcitol.
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translocation to the mitochondria, causing activation of
caspase-9, which then cleaves and activates the effector
caspase, caspase-3, leading to a loss of mitochondrial
transmembrane potential and apoptotic cell death.30 In this
study, the number of TUNEL-positive cells increased after
CsA treatment. Along with these changes, CsA increased
the expression of Bax protein and cleaved caspase-3, whereas
it downregulated expression of the anti-apoptotic protein
Bcl-2. These changes were reversed by paricalcitol, confirm-
ing that paricalcitol prevents apoptosis and tubular atrophy,
likely through the inhibition of TGF-b1 expression.
In conclusion, the active vitamin D analog paricalcitol
exerts anti-inflammatory effects through the inhibition of
NF-kB and NO signaling, resulting in a reduction of TGF-b1
expression and TGF-b1-induced Smad-2/3 and MAPK
signaling in chronic CIN. This inhibition of TGF-b1 signaling
appears to attenuate CsA-induced renal tubular cell apoptosis
and fibrosis. Although further clinical randomized study of
paricalcitol as a possible renoprotective agent in CIN is
warranted, our observation provides good evidence that
paricalcitol has significant potential as a therapeutic inter-
vention for CIN.
MATERIALS AND METHODS
Animals
The experimental protocol was approved by the Institutional Animal
Care and Use Committee of Chonnam National University Medical
School. Male SpragueDawley rats weighing 180200 g were
allowed ad libitum access to a low-salt diet (0.05% sodium; Teklad
Premier, Madison, WI, USA) and tap water. CsA (Novartis Pharma,
Basel, Switzerland) was dissolved in olive oil (Sigma Chemical,
Diagnostics, St Louis, MO, USA) to 20mg/ml. Three groups of
rats were injected with vehicle alone (n¼ 8), CsA alone (n¼ 10,
20mg/kg/day, s.c.) and CsA plus paricalcitol (0.2 mg/kg/day, s.c.;
Abbott Laboratories, North Chicago, IL, USA) (CsAþPari, n¼ 10).
Another set of rats was injected with vehicle alone (n¼ 8) and
paricalcitol alone (n¼ 8, 0.2 mg/kg/day, s.c.) for 28 days to ascertain
the proper effect of paricalcitol in rat kidney. CsA rats showed 20%
mortality rate, whereas all of the controls and CsAþPari rats
were survived during the experiments. Rats were maintained
in individual metabolic cages for the last 3 days of the experiment
to allow urine collection. On the day of the experiment, we
anesthetized the rats with isoflurane. Blood samples were collected
from the inferior vena cava. The right kidney was removed rapidly,
dissected into the cortex/OSOM, and processed for semiquantitative
immunoblotting as described below. The left kidney was fixed
through retrograde perfusion for immunohistochemistry. Another
series of experiment was conducted for the assay of real-time
polymerase chain reaction (PCR). The rats were decapitated under a
conscious state, and their kidneys were taken and kept at 70 1C
until assayed for the mRNA expression by real-time PCR.
Cell culture and application of CsA and paricalcitol
to HK-2 cells
To investigate the underlying molecular mechanisms of CsA-
induced tubule cell injury, we examined the NF-kB, MAPKs,
and EMT fibrosis and apoptotic factors in HK-2 cells. HK-2
cells were purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA) and cultured. Briefly, cells were
passaged every 3–4 days in 100-mm dishes using Dulbecco’s
modified Eagle’s medium-F12 (Sigma Chemical) supplemented
with 10% fetal bovine serum (Life Technologies, Gaithersburg, MD,
USA), 100U/ml penicillin, and 100mg/ml streptomycin (Sigma
Chemical). These cells were incubated in a humidified atmosphere
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Figure 4 | In vitro analysis of the phosphorylated nuclear factor-jB (NF-jB) p65 subunit and total IjB-a expression in HK-2 cells.
(a) Semiquantitative immunoblotting at various time points after treatment with CsA (20 mmol/l). The open bars indicate that the expression
of phosphorylated p65 subunit (P-p65) increased significantly compared to the control, beginning at 15 min after treatment and peaking at
30 min. Cytoplasmic total IkB-a expression was not significantly changed in CsA-treated cells compared to control cells. (b) In contrast,
pretreatment with paricalcitol (0.2 ng/ml) for 3 h before exposure to CsA (20 mmol/l) for 30 min suppressed the overexpression of P-p65 in
HK-2 cells. Total IkB-a expression was equivalent among control and CsA HK-2 cells with or without paricalcitol treatment. Each column
represents the mean±s.e.m. of three independent experiments performed in duplicate at each time point. *Po0.05 and **Po0.01
compared to the control. zPo0.01 compared to CsA-treated HK-2 cells. CsA, cyclosporine; Pari, paricalcitol.
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of 5% CO2, 95% air at 37 1C for 24 h and subcultured at 70–80%
confluence. For experimental use, we plated HK-2 cells onto 60-mm
dishes in medium containing 10% fetal bovine serum for 24 h and
then switched cells to Dulbecco’s modified Eagle’s medium-F12 with
2% fetal bovine serum for 16 h. These cells were treated with
CsA (10 or 20 mmol/l) in the presence or absence of paricalcitol
(0.2 ng/ml). Another set of HK-2 cells was treated with paricalcitol
alone (0.2 ng/ml) to ascertain the proper effect of paricalcitol in
HK-2 cells. Control cells received buffer only, instead of CsA or
paricalcitol. The cells were harvested at the end of the treatment for
further analysis.
Histological examination
A perfusion needle was inserted into the abdominal aorta and the
vena cava was cut to establish an outlet. Blood was flushed from
the kidney with cold phosphate-buffered saline (PBS; pH 7.4) for
15 s before switching to cold 3% paraformaldehyde in 0.1mol/l
cacodylate buffer (pH 7.4) for 3min. The kidney was removed and
cut into transverse sections 2–3mm thick, which were immersion
fixed for 1 h, followed by three 10-min washes in 0.1mol/l cacodylate
buffer, pH 7.4. The tissue was dehydrated in a graded ethanol series
and left overnight in xylene. After embedding in paraffin, we cut
sections 2mm thick on a rotary microtome (Leica Microsystems,
Herlev, Denmark). Hematoxylin and eosin staining was performed to
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Figure 5 | Effects of paricalcitol on transforming growth factor
(TGF)-b1 expression and Smad proteins in CsA-induced renal
injury. Semiquantitative immunoblotting for TGF-b1 and Smad-2/3,
Smad-4, and Smad-6 proteins. TGF-b1 expression increased
significantly in cortex/outer stripe of the outer medulla (OSOM) of
CsA-treated rats, which was markedly attenuated by paricalcitol
co-treatment. Consistent with the changes in TGF-b1, increases
in Smad-2/3 and Smad-4 protein expression suggest that TGF-b1
triggered the Smad signaling cascade. The expression of
inhibitory Smad-6 decreased in CsA-treated rats compared to
the control group. These CsA-induced changes were inhibited
by paricalcitol co-treatment. Each column represents the
mean±s.e.m. (n¼ 8). *Po0.05 and **Po0.01 compared to the
control. wPo0.05 and zPo0.01 compared to CsA-treated rats. CsA,
cyclosporine; Pari, paricalcitol.
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Figure 6 | Effects of paricalcitol on the phosphorylation of
extracellular signal-regulated kinase (pERK 1/2) and c-Jun
N-terminal kinase (pJNK) in HK-2 cells. HK-2 cells were
pretreated with paricalcitol (0.2 ng/ml) for 3 h before incubation
with CsA (20 mmol/l) for 1 h. CsA treatment increased the levels of
pERK 1/2 and pJNK, whereas paricalcitol pretreatment suppressed
these effects. Each column represents the mean±s.e.m. of three
independent experiments performed in duplicate at each time
point. **Po0.01 compared to the control. zPo0.01 compared to
CsA-treated HK-2 cells. CsA, cyclosporine; Pari, paricalcitol.
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Figure 7 | Effects of paricalcitol on the epithelial-to-
mesenchymal transition (EMT). Semiquantitative
immunoblotting revealed that CsA treatment significantly
decreased the expression of epithelial adhesion receptor
E-cadherin (a) and increased that of a-smooth muscle actin (SMA),
a molecular marker of myofibroblasts (b), consistent with tubular
EMT. In contrast, paricalcitol treatment attenuated these effects,
likely through the suppression of CsA-induced transforming
growth factor (TGF-b1) signaling. Each column represents the
mean±s.e.m. (n¼ 8). *Po0.05 and **Po0.01 compared to the
control. zPo0.01 compared to CsA-treated rats. CsA, cyclosporine;
Pari, paricalcitol.
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assess the histological tissue injury. Tubulointerstitial lesion indexes
were determined using a semiquantitative scoring system.31 Ten fields
per kidney were examined by the pathologists, and lesions were
graded from 0 to 3 (0, no change; 1, changes affectingo25% of the
section; 2, changes affecting 25–50% of the section; and 3, changes
affecting 50–100% of the section), according to the area with
tubulointerstitial lesions (tubular atrophy, interstitial inflammation,
and fibrosis). The score index in each rat was expressed as a
mean value of all scores obtained. We also performed vimentin, a
marker of actin microfilament and Masson’s trichrome to visualize
ECM accumulation and fibrosis. Masson’s trichrome staining was
quantified by image analysis (Scion Image for Windows, Scion
Corporation, Frederick, MD, USA) by the pathologists.32Randomly
selected fields (12 per section) were digitized and subjected to color
threshold analysis, giving a final average percentage positive stain per
section. Immunoperoxidase labeling was performed as described
previously.33
Semiquantitative immunoblotting
The dissected cortex/OSOM was homogenized in ice-cold isolation
solution containing 0.3mol/l sucrose, 25mmol/l imidazole, 1mmol/
l EDTA, 8.5mmol/l leupeptin, and 1mmol/l phenylmethylsulfonyl
fluoride (pH 7.2). The homogenates were centrifuged at 1000 g for
15min at 4 1C to remove whole cells, nuclei, and mitochondria.
The total protein concentration was measured. All samples were
adjusted with isolation solution to reach the same final protein
concentrations and solubilized at 65 1C for 15min in sodium
dodecyl sulfate (SDS)-containing sample buffer and then stored at
–20 1C. To confirm equal loading of protein, we stained an initial gel
with Coomassie blue. SDS–polyacrylamide gel electrophoresis was
performed on 9 or 12% polyacrylamide gels. The proteins were
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Figure 8 | Effects of paricalcitol on the expression of fibronectin
and connective tissue growth factor (CTGF). Semiquantitative
immunoblotting of (a) fibronectin and (b) CTGF expression in
HK-2 cells incubated with CsA (20mmol/l) in the absence or
presence of paricalcitol (0.2 ng/ml). CsA, cyclosporine; Pari,
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Figure 9 | Effects of CsA treatment on tubular cell apoptosis in
rats. The terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) assay revealed increased apoptosis
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Figure 10 | Effects of paricalcitol on the expression of pro-
and anti-apoptotic markers. Semiquantitative immunoblotting
indicated that the level of pro-apoptotic marker Bax increased in
CsA-treated HK-2 cells, whereas that of anti-apoptotic protein Bcl-2
decreased. Significant increases in total and cleaved caspase-3
expression were noted in CsA-treated cells. Paricalcitol also
attenuated all of these changes. CsA, cyclosporine; Pari, paricalcitol.
Each column represents the mean±s.e.m. of three independent
experiments performed in duplicate. **Po0.01 compared to the
control. zPo0.01 compared to CsA-treated HK-2 cells.
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transferred electrophoretically (Bio-Rad Mini Protean II; Bio-Rad,
Hercules, CA, USA) onto nitrocellulose membranes (Hybond ECL
RPN3032D; Amersham Pharmacia Biotech, Little Chalfont, UK).
The blots were blocked with 5% milk in PBS-T (80mmol/l
Na2HPO4, 20mmol/l NaH2PO4, 100mmol/l NaCl, and 0.1% Tween
20 (pH 7.5)) for 1 h and then incubated overnight at 4 1C with
primary antibodies, followed by incubation with secondary anti-
rabbit, anti-mouse, or anti-goat horseradish peroxidase-conjugated
antibodies. Labeling was visualized using an enhanced chemilumi-
nescence system.
Primary antibodies
The antibodies used were as follows: affinity-purified anti-mouse
antibodies against ED-1 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), iNOS (BD Transduction Laboratories, San Jose, CA, USA),
E-cadherin (BD Transduction), a-SMA (Sigma Chemical), and
fibronectin (Santa Cruz Biotechnology); and anti-rabbit antibodies
against phospho-NF-kB p65 (P-p65; Cell Signaling Technology,
Beverly, MA, USA), IkB-a (Santa Cruz Biotechnology), TGF-b1
(Santa Cruz Biotechnology), Smad-2/3 (Cell Signaling Technology),
Smad-4 (Cell Signaling Technology), Smad-6 (Cell Signaling
Technology), pERK 1/2 (Cell Signaling Technology), Bax (Cell
Signaling Technology), Bcl-2 (Cell Signaling Technology), total
caspase-3 (Cell Signaling Technology), cleaved caspase-3 (Cell
Signaling Technology); and anti-goat antibody against vimentin
(Santa Cruz Biotechnology) and CTGF (Santa Cruz Biotechnology).
Real-time PCR
The renal cortex was homogenized in TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). RNA was extracted with chloroform,
precipitated with isopropanol, washed with 75% ethanol, and then
dissolved in distilled water. The mRNA expression of inflammatory
cytokines and adhesion molecules was determined by real-time
PCR. First-strand cDNA was made by reverse transcribing 5 mg
aliquots of total RNA using oligo(dT) primers and Superscript
reverse transcriptase II (Invitrogen). Then, cDNA was quantified
using the Smart Cycler II System (Cepheid, Sunnyvale, CA, USA)
and SYBR Green was used for detection. PCR was performed with
10 mmol/l forward primer, 10 mmol/l reverse primer, 2 SYBR
Green Premix Ex Taq (Takara Bio, Seta, Japan), 0.5 ml of cDNA, and
H2O to bring the final volume to 20 ml. Relative levels of mRNAwere
determined by real-time PCR, using a Rotor-Gene 3000 Detector
System (Corbett Research, New South Wales, Australia). The
sequences of primers are listed in Table 2.
PCR was performed according to the following steps: (1) 95 1C
for 5min; (2) 95 1C for 20 s; (3) 58–62 1C for 20 s (optimized for
each primer pair); (4) 72 1C for 30 s; and (5) 85 1C for 6 s to detect
SYBR Green. Steps 2–5 were repeated for an additional 64 cycles. At
the end of the last cycle, the temperature was increased from 60 to
95 1C to produce a melting curve. Data from the reaction were
collected and analyzed with the appropriate software package from
Corbett Research. The comparative critical threshold (Ct) values
from quadruplicate measurements were used to calculate the gene
expression, with normalization against glyceraldehyde 3-phosphate
dehydrogenase as an internal control.34 Melting curve analysis
was performed to enhance the specificity of the amplification
reaction.
TUNEL assay
Apoptosis was assessed using the TUNEL assay and the numbers of
apoptotic cells, as defined by chromatin condensation or nuclear
fragmentation, were counted. Apoptosis was detected in the
specimen using the ApopTag Plus Peroxidase In Situ Apoptosis
Detection Kit (Chemicon, Temecula, CA, USA) according to the
manufacturer’s protocol. TUNEL-positive cells were counted in the
cortical tubular cells in ten  100 fields per slide.
Statistical analysis
Results are expressed as the mean±standard error of the mean
(s.e.m.). Multiple comparisons among three groups (control, CsA
alone, and CsAþPari) were performed using one-way analysis of
variance and the post hoc Tukey’s honestly significant difference test.
In another experiment for control and paricalcitol alone groups, we
use the independent t-test to compare the variables. Differences with
values of Po0.05 were considered significant.
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